Yvonne Pak Selected Research

Yvonne Pak Research Topics

4	Neoplasms (Cancer) 12/2021 - 02/2013
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 12/2021 - 02/2013
2	Experimental Arthritis 01/2017 - 12/2014
2	Inflammation (Inflammations) 12/2014 - 02/2012
2	Thrombosis (Thrombus) 07/2011 - 02/2011
1	Tumor Lysis Syndrome 12/2021
1	Residual Neoplasm 12/2021
1	Multiple Myeloma 11/2018
1	Autoimmune Diseases (Autoimmune Disease) 01/2017
1	Splenomegaly 12/2014
1	Lymphoma (Lymphomas) 12/2014
1	B-Cell Leukemia (Leukemia, B Cell) 12/2014
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 02/2013
1	Rheumatoid Arthritis 02/2012
1	Hemorrhage 07/2011
1	Wounds and Injuries (Trauma) 07/2011
1	Thrombocytopenia (Thrombopenia) 02/2011
1	Drug Eruptions (Drug Eruption) 01/2006

3	Syk KinaseIBA 01/2017 - 02/2012
2	ibrutinibIBA 12/2021 - 11/2018
2	4- (3- (2H- 1,2,3- triazol- 2- yl)phenylamino)- 2- (2- aminocyclohexylamino)pyrimidine- 5- carboxamideIBA 01/2017 - 02/2013
2	Phosphotransferases (Kinase)IBA 12/2014 - 02/2013
1	venetoclaxIBA 12/2021
1	carfilzomibIBA 11/2018
1	Bortezomib (Velcade)FDA Link 11/2018
1	B-Cell Antigen Receptors (B Cell Antigen Receptors)IBA 12/2014
1	4- (cyclopropylamino)- 2- ((4- (4- (ethylsulfonyl)piperazin- 1- yl)phenyl)amino)pyrimidine- 5- carboxamideIBA 12/2014
1	AutoantibodiesIBA 12/2014
1	fludarabineIBA 02/2013
1	ThienopyridinesIBA 07/2011
1	ferric chlorideIBA 07/2011
1	elinogrelIBA 07/2011
1	Prasugrel Hydrochloride FDA Link 07/2011
1	Clopidogrel (Plavix)FDA Link 07/2011
1	Heparin (Liquaemin)FDA LinkGeneric 02/2011
1	2- (2- aminocyclohexylamino)- 4- (m- tolylamino)pyrimidine- 5- carboxamideIBA 02/2011
1	AntibodiesIBA 02/2011
1	Platelet Factor 4IBA 02/2011
1	Antigen-Antibody Complex (Immune Complex)IBA 02/2011
1	Antipyrine (Phenazone)FDA Link 01/2006